Addiction. Opioid dependence, in remission
Conditions
Interventions
Intervention 1: Intervention group: Unified transdiagnostic group therapy. This type of therapy identifies and targets factors that are common to multiple mental disorders. The 12-session protocol of
2011) will be used. This protocol consists of 12 60-minute sessions. Intervention 2: Intervention group 2: Cognitive-Behavioral Therapy (CBT) is a psychotherapy approach that uses a combination of cog
Sponsors
Tabassom Saeid par var
Eligibility
Sex/Gender
Male
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Men with features of opioid use disorder in a Therapeutic Community Do not have a psychiatric disorder Have no history of specific medical disorders (such as head trauma, seizures, etc.) Literacy at least up to the first year of high school Recording the amount and type of sleeping medication used and being under treatment for at least three months in addiction treatment centers Willingness to participate in the study (informed consent) Treatment started within the last month Assessing substance use history and type(s) of substance used
Exclusion criteria
Exclusion criteria: Simultaneous use of multiple addictive substances Comorbidity with severe psychiatric disorders such as bipolar disorder, psychotic disorders, and other disorders that may overshadow the therapeutic relationship No motivation for treatment Mental retardation/disability Having a history of previous psychological interventions, especially CBT Diagnosis of a comorbid condition such as schizophrenia or bipolar disorder, or other conditions specifically other than impulsivity and sleep problems Changing the dosage of sleep medications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comorbid sleep problems are the scores that subjects obtain on the Morin Insomnia Severity Index (ISI) (1993). Emotional disturbance is the score that the subject receives on the Depression, Anxiety, Stress Scale (DASS, Lavibond & Lavibond, cited in Anthony et al., 1998). Craving is the score that participants obtain on the Drug Craving Questionnaire (DDQ) developed by Franken et al. (2002). Relapse prevention is actually the result that the subject obtains on the Morphine Trial (TLC), such that a positive result indicates relapse and re-use, and a negative result indicates relapse prevention. Timepoint: The beginning of the study, the end of the study (about two months), and the two-month follow-up after treatment. Method of measurement: Drug Craving Questionnaire (DDQ). Morphine Test (TLC). Morin Insomnia Severity Index (ISI). Depression, Anxiety, Stress Scale (DASS). Unified Transdiagnostic Group Therapy (UP). Cognitive Behavioral Group Therapy (CBT). Psychiatric Symptom Checklist - Short Form (SCL-25). Structured Clinical Interview (SCID). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contacttabassom saeid par var
Iran University of Medical Sciences
Outcome results
None listed